Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD
Business Of Biotech
00:00
The Future of Antibody Drug Conjugation
We acquired the whole pipeline from Bayer, German Goliath. And initially, the idea was focused on the antibody drug conjugates. We have two, a VIP 943, which has a target for CD123 for AML and MBS. Then we have another antibody that's targeting CXCR5, which is first in class. It's highly expressed in B cell malignancies like diffused large B cell, CLL,. follicular lymphoma, et cetera. But we also from Bayer acquired a CDK 9 inhibitor that I believe is truly best in class CDK 9 inhibitors.
Transcript
Play full episode
